Disease · MONDO_0003865

acral lentiginous melanoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acral lentiginous melanoma. Diseases, record MONDO_0003865. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003865

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acral lentiginous melanoma; Open Targets
Open Targets ID: MONDO_0003865; Open Targets
Other names: acral lentiginous malignant melanoma, acral lentiginous melanoma (disease), acral lentiginous melanoma, malignant, acral lentiginous melanoma, malignant (morphologic abnormality); Open Targets
Disease Ontology: DOID:6367; Disease Ontology
NCI Thesaurus: C4022; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 21 of its 30 drugs, from ClinicalTrials.gov; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DASATINIB ANHYDROUS	CHEMBL1421	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RIVOCERANIB	CHEMBL3186534	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DABRAFENIB	CHEMBL2028663	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets53

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
ABL1	Bcr/Abl fusion protein	3	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	3	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
KDR	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	2	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	2	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets

1 to 10 of 53

See all 53 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02879162	Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours	Phase 2	140	2025-02-17	Advanced Rare Tumours	DURVALUMAB, TREMELIMUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00700882	Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery	Phase 2	81	2020-02-24	Melanoma (Skin)	DASATINIB ANHYDROUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT02083354	Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma	Phase 2	77	2021-03-17	Cancer, Melanoma	DABRAFENIB, TRAMETINIB	Its record names the disease	ClinicalTrials.gov
NCT00577382	SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma	Phase 2	52	2016-12-08	Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00424515	Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma	Phase 2	24	2016-12-08	Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas	IMATINIB	Its record names the disease	ClinicalTrials.gov
NCT01092728	Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma	Phase 2	19	2016-09-05	Melanoma	DASATINIB ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT02978443	A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab	Phase 2	14	2024-04-04	Acral Lentiginous Melanoma, Mucosal Melanoma	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02875132	Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma	Phase 2	9	2025-04-18	Acral Lentiginous Melanoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04485013	TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	Phase 1	240		Cancer	CETUXIMAB, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06797297	A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy	Phase 2	203		Melanoma	PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort A-Sunitinib Intermittent Dosing vs Cohort B-Sunitinib Continuous Dosing: serious adverse events	10 of 21	13 of 31	52	NCT00577382	Trial comparisons
Amplified KIT vs Mutated KIT: serious adverse events	1 of 11	3 of 13	24	NCT00424515	Trial comparisons
Dasatinib + Completely Resectable vs Dasatinib + Unresectable: serious adverse events	0 of 4	4 of 14	18	NCT01092728	Trial comparisons

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39737219	RESULT	1	PubMed
28334439	RESULT	1	PubMed
26264378	RESULT	1	PubMed
37261804	DERIVED	1	PubMed
36753834	DERIVED	1	PubMed
34858178	DERIVED	1	PubMed
34504796	DERIVED	1	PubMed
33770575	DERIVED	1	PubMed
33377972	DERIVED	1	PubMed
32534242	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003865

GET https://conductscience.org/api/diseases/v1/MONDO_0003865/drugs?page=2

API reference For AI assistants